Daewoong Pharmaceutical Targets Indonesia with 'K-Aesthetic Total Solution'

Five Major Aesthetic Products Including Toxin, Filler, and Thread Introduced

Daewoong Pharmaceutical and DNC Aesthetics announced on July 21 that they held the "CGBio Launching Symposium" at the Langham Hotel in Jakarta, Indonesia, on the 19th, introducing five major aesthetic products to the Indonesian market.

Over 100 Indonesian dermatologists and aesthetic medicine specialists attended the "CGBio Launching Symposium" held at the Langham Hotel in Jakarta, Indonesia, on the 19th, where they received shared clinical case-based combination treatment techniques. Daewoong Pharmaceutical

According to Daewoong Pharmaceutical, the launch focused not only on product supply but also on providing combination treatment training that could be immediately applied in clinical practice, thereby increasing practical utility on site. The symposium was attended by approximately 100 Indonesian dermatologists and aesthetic medicine specialists, who received shared clinical case-based combination treatment techniques.

Yoon Chunshik, Director of Yemione Dermatology Clinic, who introduced facial procedure know-how, stated, "Nabota is a product with verified high purity and quality stability, which reduces immunogenicity and delivers consistent results, making it a reliable option in real-world clinical settings." He also introduced facial procedure techniques using aesthetic products such as Nabolift.

'Nabolift' is a treatment method developed by Daewoong Pharmaceutical. By injecting botulinum toxin into the skin and muscle layers, it induces complex cosmetic effects such as facial contour lifting, wrinkle improvement, and skin texture enhancement.

Dr. Ineke Jane of Youth and Beauty Clinic in Indonesia added, "After administering Nabota for glabellar lines, I observed a rapid and natural effect. I am confident that these results are fully applicable to Indonesian patients, which is why I wanted to share my treatment experience."

Experiences with filler products were also shared. Joo Hongjin, Director of Glassy Dermatology Clinic, who presented a neck wrinkle treatment method using DCLASSY CaHA, said, "DCLASSY CaHA is a product with biostimulation capabilities that induce collagen production, making it excellent for sustained skin elasticity improvement. It was a meaningful opportunity to share know-how that aligns with Indonesian beauty trends."

DCLASSY is a premium aesthetic brand scheduled for launch in Indonesia in the second half of 2025. Both of its two core lineups?HA fillers and CaHA formulations?are high-quality products developed with proprietary technology. The HA fillers are available in three formulations with optimized viscoelastic balance, enabling more stable and delicate procedures. The CaHA formulation, with its patented perfectly spherical structure, gradually decomposes from the outer wall, continuously inducing collagen production and delivering a natural elasticity improvement effect.

This symposium was organized through "KIIMOT," an integrated organization jointly established by Daewoong and DNC Aesthetics. KIIMOT focuses on systematically training local medical professionals in Daewoong's combination treatment know-how, thereby fostering an environment where both procedural techniques and products can advance together.

Ha Changwoo, Head of KIIMOT, stated, "Indonesia is a strategically key market with both a rapidly growing medical aesthetics sector and a high preference for K-beauty. Based on Daewoong's globally recognized product capabilities and procedural expertise, we will work with local Indonesian medical professionals to further develop combination treatment methods and systematically train specialized personnel through the 'DEEP' program, thereby establishing the standard of Korean medical aesthetics in Indonesia."